Your browser doesn't support javascript.
loading
Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine.
Bhatla, Neerja; Muwonge, Richard; Malvi, Sylla G; Joshi, Smita; Poli, Usha Rani Reddy; Lucas, Eric; Esmy, Pulikkottil O; Verma, Yogesh; Shah, Anand; Zomawia, Eric; Pimple, Sharmila; Jayant, Kasturi; Hingmire, Sanjay; Chiwate, Aruna; Vashist, Shachi; Mishra, Gauravi; Jadhav, Radhika; Siddiqi, Maqsood; Anantharaman, Devasena; Panicker, Gitika; Butt, Julia; Sankaran, Subha; Kannan, Thiraviam Pillai Rameshwari Ammal; Varghese, Rintu; Kartha, Purnima; Pillai, M Radhakrishna; Waterboer, Tim; Müller, Martin; Sehr, Peter; Unger, Elizabeth R; Sankaranarayanan, Rengaswamy; Basu, Partha.
Afiliación
  • Bhatla N; Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
  • Muwonge R; Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France.
  • Malvi SG; Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Solapur, India.
  • Joshi S; Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India.
  • Poli URR; Public Health Foundation of India, IIPH-H, Hyderabad, India.
  • Lucas E; Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France.
  • Esmy PO; Department of Oncology, Christian Fellowship Community Health Centre, Ambillikai (near Oddanchathram), India.
  • Verma Y; Sikkim Manipal Institute of Medical Sciences, Sikkim Manipal University, Gangtok, India.
  • Shah A; Gujarat Cancer & Research Institute (GCRI), M.P. Shah Cancer Hospital, Civil Hospital Campus, Ahmedabad, India.
  • Zomawia E; National Health Mission, Civil Hospital, Aizawl, India.
  • Pimple S; Department of Preventive Oncology, Centre for Cancer Epidemiology (CCE), Homi Bhabha National Institute, Tata Memorial Centre, Mumbai, India.
  • Jayant K; Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Solapur, India.
  • Hingmire S; Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Solapur, India.
  • Chiwate A; Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Solapur, India.
  • Vashist S; Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
  • Mishra G; Department of Preventive Oncology, Centre for Cancer Epidemiology (CCE), Homi Bhabha National Institute, Tata Memorial Centre, Mumbai, India.
  • Jadhav R; Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India.
  • Siddiqi M; Cancer Foundation of India, Kolkata, India.
  • Anantharaman D; Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.
  • Panicker G; National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Butt J; Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Sankaran S; Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.
  • Kannan TPRA; Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.
  • Varghese R; Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.
  • Kartha P; Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.
  • Pillai MR; Cancer Research Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.
  • Waterboer T; Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Müller M; Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Sehr P; EMBL-DKFZ Chemical Biology Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany.
  • Unger ER; National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Sankaranarayanan R; Kerala Operations, Karkinos Healthcare, Ernakulam, India.
  • Basu P; Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France.
Hum Vaccin Immunother ; 19(3): 2289242, 2023 Dec 15.
Article en En | MEDLINE | ID: mdl-38078840
Long-term follow-up of a cohort of unmarried girls who received one, two, or three doses of quadrivalent HPV vaccine, between 10 and 18 years of age, in an Indian multi-centric study allowed us to compare antibody responses between the younger and older age cohorts at 10-years post-vaccination, and study the impact of initiation of sexual activity and cervical HPV infections on antibody levels. Among the younger (10-14 years) recipients of a single dose, 97.7% and 98.2% had detectable binding antibody titers against HPV 16 and HPV 18 respectively at ten years post-vaccination. The proportions among those receiving a single dose at age 15-18 years were 92.3% and 94.2% against HPV 16 and HPV 18 respectively. Mean HPV 16 binding antibody titers were 2.1 folds (95%CI 1.4 to 3.3) higher in those vaccinated at ages 10-14 years, and 1.9 folds (95%CI 1.2 to 3.0) higher in those vaccinated at 15-18 years compared to mean titers seen in the unvaccinated women. Compared to previous timepoints of 36 or 48 months, binding antibodies against HPV 16 and neutralizing antibodies against both HPV 16 and HPV 18 were significantly higher at 10 years. This rise was more pronounced in participants vaccinated at 15-18 years. No association of marital status or cervical HPV infections was observed with the rise in titer. Durability of antibody response in single dose recipients correlated well with the high efficacy of a single dose against persistent HPV 16/18 infections irrespective of age at vaccination, as we reported earlier.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Papillomavirus / Vacunas contra Papillomavirus Límite: Adolescent / Child / Female / Humans Idioma: En Revista: Hum Vaccin Immunother Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Papillomavirus / Vacunas contra Papillomavirus Límite: Adolescent / Child / Female / Humans Idioma: En Revista: Hum Vaccin Immunother Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos